Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) ##STR00001##
in which
A, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description,
and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.

Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) ##STR00001##
in which
A, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description,
and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.

This disclosure relates to GLP-1 agonists of Formula I:

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

This disclosure relates to GLP-1 agonists of Formula I:

##STR00001##

including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments. ##STR00001##

The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments. ##STR00001##

The invention relates to the treatment of actinic keratosis on the scalp with ingenol 3-(3,5-diethylisoxazole-4-carboxylate).

The invention relates to the treatment of actinic keratosis on the scalp with ingenol 3-(3,5-diethylisoxazole-4-carboxylate).

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.